Experiment 909594

Details

PropertyValue
Pharmacology
Administration routeIV INFUSION
OrganismEmpty organism
CitationANON:. (1990). TAXOL.. 15(1)
Amount utilized
Compound isolated
Disease26 PATIENTS WERE TREATED IN A PHASE I TRIAL. PERIPHERAL NEUROPATHY WAS THE DOSE LIMITING TOXICITY. OTHER SIDE EFFECTS INCLUDED NEUTROPENIA. PR OF 13-22 WEEKS SEEN IN 4/12 PATIENTS. RECOMMENDED DOSE FOR PHASE II TRIAL WAS 250.0 MG/SQ.M.
Dose amountVAR
Number6
Qualitative result.
AnimalHUMAN ADULT
Dose expressionDOSE